
---
title: '上海阳性感染者中药使用率超98%，板块掀涨停潮，14股获北向资金加仓，3股一季度业绩预喜'
categories: 
 - 金融
 - 证券时报网
 - 数据
headimg: 'https://data.stcn.com/djsj/202204/W020220406659783525909.jpeg'
author: 证券时报网
comments: false
date: Wed, 06 Apr 2022 18:16:00 GMT
thumbnail: 'https://data.stcn.com/djsj/202204/W020220406659783525909.jpeg'
---

<div>   
<p style="text-align: left;">中药板块表现强势，多家公司产品被列入新版新冠诊疗方案。</p><p style="text-align: left;"><strong>中药板块多股涨停</strong></p><p style="text-align: left;">中药板块今日表现强势，有10股涨停，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002589" code="002589">瑞康医药</a>3连板，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ000566" code="000566">海南海药</a>2连板，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS603963" code="603963">大理药业</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002566" code="002566">益盛药业</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ000590" code="000590">启迪药业</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002603" code="002603">以岭药业</a>等股涨停。</p><p style="text-align:center"><img data-ratio="1.7768519" src="https://data.stcn.com/djsj/202204/W020220406659783525909.jpeg" data-type="jpeg" data-w="1080" data-imgqrcoded="1" width="500px" height="888.425925925926px" style="width: 500px; height: 888.426px;" oldsrc="W020220406659783525909.jpeg" referrerpolicy="no-referrer"></p><p style="text-align: left;">今年以来，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002864" code="002864">盘龙药业</a>的股价累计上涨139.58%，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600381" code="600381">青海春天</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002349" code="002349">精华制药</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002603" code="002603">以岭药业</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300158" code="300158">振东制药</a>的股价累计涨幅均超50%。</p><p style="text-align: left;">消息面上，世界卫生组织关于中医药治疗新冠肺炎专家评估会的报告于3月31日在世卫组织官网发布，来自世卫组织6个区域的21名国际专家参加了评估会，会议报告指出：中药能有效治疗新冠肺炎，降低轻型、普通型病例转为重症，缩短病毒清除时间，改善轻型和普通型患者的临床预后。报告同时鼓励成员国考虑中国形成并应用的整合医学模式（中西医结合模式）；有效管理当前疫情并对未来可能发生的大流行做好准备。</p><p style="text-align: left;"><strong>上海阳性感染者中药使用率98%以上</strong></p><p style="text-align: left;">随着上海等地疫情的出现，中药在其中的应用也越来越受到重视。据央视新闻报道，在4月5日举行的上海市疫情防控工作新闻发布会上，上海中医药大学附属曙光医院院长、中医疫病防治基地负责人房敏表示中医药在新冠疫情防控中发挥了积极作用，上海针对阳性感染者，中药使用率稳定保持在98%以上。</p><p style="text-align: left;">3月初，上海市卫健委、上海市中医药管理局发布了由国家中医疫病防治基地制定的《2022年春季易感人群外感疫病中药内服预防方案》，向隔离点及重点封控的街镇、小区、楼宇人群提供中药预防方药，深受群众欢迎。在此基础上，开展面向全市全人群、全覆盖的中医药预防干预工作，目前已累计向各街镇配送超过2100万人份中药预防方药，对尽快建立防疫屏障起到了积极作用。</p><p style="text-align: left;">此外， 3月14日，国家卫健委、国家中医药管理局再次联合发布《新型冠状病毒肺炎诊疗方案（试行第九版）》，就突出了中医药治疗，就诊疗各阶段提出了相应中医药诊疗方案。</p><p style="text-align: left;">具体到上市公司方面，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300026" code="300026">红日药业</a>的血必净注射液、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS603858" code="603858">步长制药</a>的宣肺败毒颗粒、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002603" code="002603">以岭药业</a>的连花清瘟胶囊（颗粒）、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600129" code="600129">太极集团</a>的藿香正气口服液等产品被列入新型冠状病毒肺炎诊疗方案（试行第九版）。</p><p style="text-align: left;"><strong>多股获北向资金加仓</strong></p><p style="text-align: left;">首创证券指出，在新冠疫情之中，中医药发挥了重大作用，近年来随着高层对中医药事业的重视程度不断提升，各类支持中医药发展的政策陆续出台。特别是在2020-2021年，中医药行业利好政策密集出台，涉及到药品审评、临床使用、医保支付、医疗服务体系建设等诸多方面，中医药行业政策环境大幅度好转，行业有望迎来拐点。</p><p style="text-align: left;">证券时报·数据宝统计，板块中<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600085" code="600085">同仁堂</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600436" code="600436">片仔癀</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ000999" code="000999">华润三九</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ000423" code="000423">东阿阿胶</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002603" code="002603">以岭药业</a>等9股均有5家以上机构评级。</p><p style="text-align: left;">资金面上，14股获北向资金青睐。3月以来，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ000423" code="000423">东阿阿胶</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600332" code="600332">白云山</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002603" code="002603">以岭药业</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600993" code="600993">马应龙</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600285" code="600285">羚锐制药</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300026" code="300026">红日药业</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600252" code="600252">中恒集团</a>等14股的获得北上资金累计净买入；<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ000423" code="000423">东阿阿胶</a>的北上资金累计净买入额最多，为6.48亿元。</p><p style="text-align: left;">数据宝统计，业绩方面，按照年报或预告下限计算，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600518" code="600518">*ST康美</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600332" code="600332">白云山</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ000538" code="000538">云南白药</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300158" code="300158">振东制药</a>等7股的2021年归母净利润额超20亿元，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ000423" code="000423">东阿阿胶</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300158" code="300158">振东制药</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600572" code="600572">康恩贝</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ002773" code="002773">康弘药业</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600538" code="600538">国发股份</a>等14股的业绩同比翻倍增长。</p><p style="text-align: left;">有3股已经抢先发布了今年一季度的业绩预告，<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SZ300181" code="300181">佐力药业</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600750" code="600750">江中药业</a>、<a class="trsHotWords" style="color: #2f67d1;text-decoration: none;" target="_blank" href="https://info.stcn.com/dc/stock/?stockcode=SS600436" code="600436">片仔癀</a>均预增。（数据宝 郭洁）</p><p style="text-align:center"><img data-ratio="0.7272727" src="https://data.stcn.com/djsj/202204/W020220406659785912176.png" data-type="png" data-w="770" data-imgqrcoded="1" width="500px" height="363.6363636363636px" style="width: 500px; height: 363.636px;" oldsrc="W020220406659785912176.png" referrerpolicy="no-referrer"></p><p style="text-align: left;">声明：数据宝所有资讯内容不构成投资建议，股市有风险，投资需谨慎。</p>
  
</div>
            